Get the Whole Story Here.
Published loading...Updated

US CDC panel backs Pfizer's maternal RSV vaccine to protect infants

  • The U.S. Centers for Disease Control and Prevention panel backed Pfizer's RSV vaccine for pregnant women in their third trimester to protect their babies from severe illness.
  • The Pfizer vaccine was approved by the FDA for use during weeks 32 to 36 of pregnancy to prevent RSV in infants. The CDC panel's recommendation will make it the first maternal vaccine for the seasonal respiratory virus available in the country.
  • The vaccine's efficacy is high during the first 90 days after birth, preventing severe RSV disease in newborns, but the effectiveness slightly lowers over time.
Insights by Ground AI
Does this summary seem wrong?

59 Articles

All
Left
8
Center
45
Right
1
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 83% of the sources are Center
83% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Forbes broke the news in United States on Friday, September 22, 2023.
Sources are mostly out of (0)